BH3模拟物与阿扎胞苷对幼年型粒单核细胞白血病显示协同效应
幼年型粒单核细胞白血病(JMML)由持续活化的RAS信号驱动,多数患者需造血干细胞移植但部分亚型复发风险高;阿扎胞苷仅对部分患者有效且存在耐药风险。研究者在既往建立的患者来源异种移植模型中,将多种BH3模拟物与阿扎胞苷联合,发现JMML细胞同时依赖MCL-1和BCL-XL存活,阿扎胞苷体内通过下调抗凋亡MCL-1、上调促凋亡BH3-only蛋白发挥作用,阿扎胞苷联合BCL-XL抑制优于联合BCL-2抑制。
要点
- JMML细胞存活同时依赖MCL-1和BCL-XL两种抗凋亡蛋白。
- 阿扎胞苷体内下调MCL-1并上调促凋亡BH3-only蛋白。
- 阿扎胞苷联合BCL-XL抑制在清除JMML细胞上优于联合BCL-2抑制。
核心结论
- JMML细胞同时依赖MCL-1和BCL-XL存活,阿扎胞苷与BH3模拟物联合可有效靶向这两种蛋白。
- 阿扎胞苷联合BCL-XL抑制在清除JMML细胞上优于联合BCL-2抑制。
- 作者强调需开发临床可用的MCL-1或BCL-XL抑制剂,以便为标准化疗难治的JMML提供新型联合治疗。
研究设计与样本
- 研究在既往建立的患者来源异种移植模型中进行,将多种BH3模拟物与阿扎胞苷联合。
主要发现
- JMML细胞存活同时需要MCL-1和BCL-XL。
- 阿扎胞苷在体内通过下调抗凋亡蛋白MCL-1并上调促凋亡BH3-only蛋白发挥作用。
- 阿扎胞苷联合BCL-XL抑制在消除JMML细胞方面优于联合BCL-2抑制。
临床怎么用
- 作者认为需开发临床可用的MCL-1或BCL-XL抑制剂,以在标准化疗难治的JMML中实现新型联合治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Juvenile myelomonocytic leukemia (JMML) is an aggressive hematopoietic disorder of infancy and early childhood driven by constitutively active RAS signaling and characterized by abnormal proliferation of the granulocytic-monocytic blood cell lineage. Most JMML patients require hematopoietic stem cell transplantation for cure, but the risk of relapse is high for some JMML subtypes. Azacitidine was shown to effectively reduce leukemic burden in a subset of JMML patients. However, variable response rates to azacitidine and the risk of drug resistance highlight the need for novel therapeutic approaches. Since RAS signaling is known to interfere with the intrinsic apoptosis pathway, we combined various BH3 mimetic drugs with azacitidine in our previously established patient-derived xenograft model. We demonstrate that JMML cells require both MCL-1 and BCL-XL for survival, and that these proteins can be effectively targeted by azacitidine and BH3 mimetic combination treatment. In vivo azacitidine acts via downregulation of antiapoptotic MCL-1 and upregulation of proapoptotic BH3-only. The combination of azacitidine with BCL-XL inhibition was superior to BCL-2 inhibition in eliminating JMML cells. Our findings emphasize the need to develop clinically applicable MCL-1 or BCL-XL inhibitors in order to enable novel combination therapies in JMML refractory to standard therapy.
引用
- Wu Y, Zehnle PMA, Rajak J, et al. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia. Leukemia. 2023. PMID: 37945692. doi:10.1038/s41375-023-02079-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。